Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Nexstim Plc: Managers’ Transactions, Niemistö | ||
By: GlobeNewswire - 25 Apr 2024 | Back to overview list |
|
Company Announcement, Helsinki, 25 April 2024 at 1 PM (EEST) Nexstim Plc: Managers’ Transactions, Niemistö Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers’ transactions as follows: Person subject to the notification requirement ____________________________________________ Transaction details Aggregated transactions (1): Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO The Company’s Certified Advisor is Carnegie Investment Bank AB (publ). About Nexstim Plc Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain. Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain. Nexstim shares are listed on Nasdaq First North Growth Market Finland. For more information, please visit www.nexstim.com Attachment |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |